Tumor necrosis factor-α in the pathogenesis and treatment of cancer

Current Opinion in Pharmacology

Volumn 4, Issue 4, 2004, Pages 314-320

  Anderson, G Mark ^a   Nakada, Marian T ^a   DeWitte, Mark ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CERTOLIZUMAB PEGOL; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 2; MELPHALAN; MESSENGER RNA; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BONE PAIN; CACHEXIA; CANCER PAIN; CARCINOGENESIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOLOGY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EVIDENCE BASED MEDICINE; FATIGUE; GRAFT VERSUS HOST REACTION; HISTOPLASMOSIS; HUMAN; HYPOTENSION; KIDNEY INJURY; LISTERIOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMIC DISEASE; TUBERCULOSIS; TUMOR GROWTH; TUMOR PROMOTION; VIRUS REACTIVATION;

EID: 3342968806     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.04.004     Document Type: Review

References (63)

1. Palladino M.A. Bahjat F.R. Theodorakis E.A. Moldawer L.L. Anti-TNF-alpha therapies: the next generation Nat Rev Drug Discov 2 2003 736-746
2. Younes A. Kadin M.E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy J Clin Oncol 21 2003 3526-3534
3. Younes A. Aggarwall B.B. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders Cancer 98 2003 458-467
4. Eggermont A.M. ten Hagen T.L. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy Curr Oncol Rep 5 2003 79-80
5. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy Nat Rev Cancer 4 2004 11-22
6. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 2002 135-141
7. Micheau O. Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes Cell 114 2003 181-190
8. Lejeune F.J. Ruegg C. Lienard D. Clinical applications of TNF-alpha in cancer Curr Opin Immunol 10 1998 573-580
9. Eggermont A.M. de Wilt J.H. ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol 4 2003 429-437
10. Folli S. Pelegrin A. Chalandon Y. Yao X. Buchegger F. Lienard D. Lejeune F. Mach J.P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability Int J Cancer 53 1993 829-836
11. Ruegg C. Yilmaz A. Bieler G. Bamat J. Chaubert P. Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat Med 4 1998 408-414
12. Senzer N. Mani S. Rosemurgy A. Nemunaitis J. Cunningham C. Guha C. Bayol N. Gillen M. Chu K. Rasmussen C. et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors J Clin Oncol 22 2004 592-601
13. Curnis F. Sacchi A. Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration J Clin Invest 110 2002 475-482
14. Curnis F. Gasparri A. Sacchi A. Longhi R. Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity Cancer Res 64 2004 565-571
15. Borsi L. Balza E. Carnemolla B. Sassi F. Castellani P. Berndt A. Kosmehl H. Biro A. Siri A. Orecchia P. et al. Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 2003 4384-4392
16. Szlosarek P.W. Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours Lancet Oncol 4 2003 565-573
17. Scott K.A. Moore R.J. Arnott C.H. East N. Thompson R.G. Scallon B.J. Shealy D.J. Balkwill F.R. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors Mol Cancer Ther 2 2003 445-451
18. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR: Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2003.
19. Mantovani G. Maccio A. Mura L. Massa E. Mudu M.C. Mulas C. Lusso M.R. Madeddu C. Dessi A. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites J Mol Med 78 2000 554-561
20. Karayiannakis A.J. Syrigos K.N. Polychronidis A. Pitiakoudis M. Bounovas A. Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients Anticancer Res 21 2001 1355-1358
21. Yoshida N. Ikemoto S. Narita K. Sugimura K. Wada S. Yasumoto R. Kishimoto T. Nakatani T. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma Br J Cancer 86 2002 1396-1400
22. Leek R.D. Landers R. Fox S.B. Ng F. Harris A.L. Lewis C.E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma Br J Cancer 77 1998 2246-2251
23. Partanen R. Koskinen H. Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer Occup Environ Med 52 1995 316-319
24. Pfitzenmaier J. Vessella R. Higano C.S. Noteboom J.L. Wallace D. Jr. Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma Cancer 97 2003 1211-1216
25. Bossola M. Muscaritoli M. Bellantone R. Pacelli F. Cascino A. Sgadari A. Battaglia F. Piccioni E. Scambia G. Doglietto G.B. et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss Eur J Clin Invest 30 2000 1107-1112
26. Darai E. Detchev R. Hugol D. Quang N.T. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours Hum Reprod 18 2003 1681-1685
27. Ness R.B. Endometriosis and ovarian cancer: thoughts on shared pathophysiology Am J Obstet Gynecol 189 2003 280-294
28. Tselepis C. Perry I. Dawson C. Hardy R. Darnton S.J. McConkey C. Stuart R.C. Wright N. Harrison R. Jankowski J.A. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action Oncogene 21 2002 6071-6081
29. Ferrajoli A. Keating M.J. Manshouri T. Giles F.J. Dey A. Estrov Z. Koller C.A. Kurzrock R. Thomas D.A. Faderl S. et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia Blood 100 2002-1215 1219
30. Tsimberidou A.M. Giles F.J. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies Expert Rev Anticancer Ther 2 2002 277-286
31. Korngold R. Marini J.C. de Baca M.E. Murphy G.F. Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses Biol Blood Marrow Transplant 9 2003 292-303
32. Jacobsohn D.A. Hallick J. Anders V. McMillan S. Morris L. Vogelsang G.B. Infliximab for steroid-refractory acute GVHD: a case series Am J Hematol 74 2003 119-124
33. Couriel DR, Saliba R, Hicks K, Cohen A, Ippoliti C, Neumann J, Giralt S, De Lima MJ, Champlin R: ASH 44th annual meeting, 6-10 December 2002, Philadelphia, PA [Abstract 3343].
34. Marty F.M. Lee S.J. Fahey M.M. Alyea E.P. Soiffer R.J. Antin J.H. Baden L.R. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study Blood 102 2003 2768-2776
35. Campos A, Vaz CP, Costa N, Mendes J, Roncon S, Barbosa I, Carvalhais A, Campilho F, Pimentel P: ASH 45th Annual Meeting, 6-9 December 2003, San Diego, CA [Abstract 5528].
36. Stasi R. Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes Br J Haematol 116 2002 334-337
37. Raza A, Lisak LA, Tahir S, Billmeier JM, Willmann HS, Bellak DJ, Alvi MI, Gezer S, Venugopal P: ASH 44th Annual Meeting, 6-10 December 2002, Philadelphia, PA [Abstract 3141].
38. Trehu E.G. Mier J.W. Dubois J.S. Sorce D. Klempner M.S. Epstein M. Dinarello C.A. Shapiro L. Kappler K. Ronayne L. et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera Clin Cancer Res 2 1996 1341-1351
39. Tsimberidou A.M. Waddelow T. Kantarjian H.M. Albitar M. Giles F.J. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment Leuk Res 27 2003 375-380
40. Scallon B. Cai A. Solowski N. Rosenberg A. Song X.Y. Shealy D. Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418-426
41. Anderson K. Moving disease biology from the laboratory to the clinic Semin Oncol 29 2002 17-20
42. Smith K.J. Skelton H.G. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy J Am Acad Dermatol 45 2001 953-956
43. Kavanaugh A. Keystone E.C. The safety of biologic agents in early rheumatoid arthritis Clin Exp Rheumatol 21 2003 S203-S208
44. Wolfe F. Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients [abstract] Arthritis Rheum 48 Suppl 2003-S242
45. Lee J.H. Slifman N.R. Gershon S.K. Edwards E.T. Schwieterman W.D. Siegel J.N. Wise R.P. Brown S.L. Udall J.N. Jr. Braun M.M. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept Arthritis Rheum 46 2002 2565-2570
46. Brown S.L. Greene M.H. Gershon S.K. Edwards E.T. Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 2002 3151-3158
47. Slifman N.R. Gershon S.K. Lee J.H. Edwards E.T. Braun M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents Arthritis Rheum 48 2003 319-324
48. Colombel J.F. Loftus E.V. Jr. Tremaine W.J. Egan L.J. Harmsen W.S. Schleck C.D. Zinsmeister A.R. Sandborn W.J. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients Gastroenterology 126 2004 19-31
49. Kurzrock R. The role of cytokines in cancer-related fatigue Cancer 92 2001 1684-1688
50. Wichers M. Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans Int J Neuropsychopharmacol 5 2002 375-388
51. Tisdale M.J. Cachexia in cancer patients Nat Rev Cancer 2 2002 862-871
52. Argiles J.M. Busquets S. Lopez-Soriano F.J. Cytokines in the pathogenesis of cancer cachexia Curr Opin Clin Nutr Metab Care 6 2003 401-406
53. Ramesh G. Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity J Clin Invest 110 2002 835-842
54. Delanian S. Porcher R. Balla-Mekias S. Lefaix J.L. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis J Clin Oncol 21 2003 2545-2550
55. Rube C.E. van Valen F. Wilfert F. Palm J. Schuck A. Willich N. Winkelmann W. Jurgens H. Rube C. Ewing's sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure Int J Radiat Oncol Biol Phys 56 2003 1414-1425
56. Azuma Y. Kaji K. Katogi R. Takeshita S. Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts J Biol Chem 275 2000 4858-4864
57. Schafers M. Lee D.H. Brors D. Yaksh T.L. Sorkin L.S. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation J Neurosci 23 2003 3028-3038
58. Tobinick E.L. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports Clin Ther 25 2003 2279-2288
59. Hecht JR, Hanna N, Chung T, Vogel S, Rosemurgy A, Nemuniatis J, Milind J, Reid T, Kessler P, Posner M et al.: Preliminary results of a dose escalation trial of TNFerade in combination with 5-fluorouracil (5-FU) and radiation in locally advanced pancreatic cancer. 95th Annual Meeting of the American Association for Cancer Research. 27-31 March 2004, Orlando, FL[Abstract number 2344].
60. Zarovni N. Monaco L. Corti A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor α coupled to NGR and RGD tumor-homing peptides Hum Gene Ther 15 2004 373-382
61. Mochizuki Y. Nakanishi H. Kodera Y. Ito S. Yamamura Y. Kato T. Hibi K. Akiyama S. Nakao A. Tatematsu M. TNF-α promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line Clin Exp Metastasis 21 2004 39-47
62. Hagemann T. Robinson S.C. Schulz M. Trumper L. Balkwill F.R. Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-(R) dependent upregulation of matrix metalloproteases. Carcinogenesis 2004, in press.
63. Fleischmann R. Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis Mol Interv 3 2003 310-318